Science
A Scientist Is Paid to Study Maple Syrup. He’s Also Paid to Promote It.
For more than a decade, Navindra Seeram, a biomedical researcher, has praised maple syrup, calling it a “hero ingredient” and “champion food” that could have wide-ranging health benefits.
Dr. Seeram, dean of the School of Pharmacy at the University of New England, has published more than three dozen studies extolling the power of maple. Much of his work has been bankrolled by Canada’s maple syrup industry and the Canadian and American governments.
At the same time, he has taken on another role: maple syrup pitchman.
“I am uniquely qualified as the world’s leading researcher on maple health benefits with the scientific reputation and credibility to promote the sales of maple products,” he has written in grant applications. He has assured leaders of the Canadian industry that he would always support maple from Quebec, according to emails obtained through a public records request.
As he straddles the realms of scientific inquiry and promotion, he has distorted the real-world implications of his findings and exaggerated health benefits, according to a review by The Examination and The New York Times of 15 years of his studies and public statements. In videos and press releases, he has suggested that consuming maple syrup may help stave off diseases including cancer, Alzheimer’s and diabetes. Other scientists told The Examination and The Times that they thought he had overstated his lab findings and made misleading claims.
Industry funding is commonplace in nutrition research and may become even more critical as scientists grapple with the Trump administration’s sweeping cuts. Dr. Seeram’s work shows the perils of intertwining science and salesmanship, propelling information that can shape consumer habits and public health.
At the University of Rhode Island, where he worked until last year, Dr. Seeram oversaw projects that were awarded $2.6 million in U.S. government funding, including a grant explicitly intended to increase maple syrup sales. That promotional work produced a stream of social media posts like, “Maple Syrup’s Benefits: Anti-Cancer, Anti-Oxidant, Anti-Inflammatory.”
In a video posted on YouTube in 2019, Dr. Seeram said nutrients in maple syrup could “potentially together prevent and/or delay the onset” of conditions such as “cardiovascular disease, metabolic syndrome, diseases of the brain and so on.”
But his studies have found something more limited: that maple syrup contains small amounts of polyphenols, compounds in plants that are generally considered beneficial. To demonstrate their effects, he tested highly concentrated maple extracts in lab settings — not people’s consumption of commercial maple syrup.
Dr. Seeram told The Examination that he believed in the power of natural medicines, which were part of his upbringing in South America. And he defended how he had spoken about his findings: “No one can go back to direct-quote from me to say, ‘It’s going to cure cancer, it’s going to cure diabetes.’”
His conclusions often include hedging language — that maple syrup “may” or “could” have meaningful health effects — or disclaimers recommending further study. But several researchers said that the caveats weren’t enough to counterbalance broad health claims, and that Dr. Seeram had leaped too far from lab findings to practical applications.
“They are framing it in a far more positive light than they should,” said Christopher Gardner, a nutrition researcher at Stanford.
In an interview, Dr. Seeram blamed a former colleague at the University of Rhode Island for stirring up what he said was unwarranted scrutiny of his work. A university official said the school had investigated and found no research misconduct.
At a maple industry conference in October, Dr. Seeram described his work as making “it simple for Mom to understand” that syrup is beneficial.
“We have to convince the consumer that this sugar is good for you,” he told an audience of maple farmers, and laid out how to reach the public: Studies like his would be published in peer-reviewed journals, leading to marketing and media coverage and inspiring consumers to buy.
The Quebec Maple Syrup Producers, an industry association that markets and regulates most of the world’s maple syrup, has long funded Dr. Seeram’s work. The association and the Canadian government have together provided at least $2.8 million for his research, according to a 2019 grant application. The association disputed that figure but would not provide details; neither would Dr. Seeram.
The association has also hired him for consulting and what it termed “PR activities” for at least a decade, according to emails and invoices. In 2023, his fees totaled $37,000, emails show.
In response to one of several emails from association officials thanking him for his work, he wrote in 2018 that he would “always work to find ways to promote maple products from Quebec.”
The maple association approached him in 2009, after the owners of POM Wonderful had funded and used some of his research on pomegranate to promote their juice during the pomegranate craze of the 2000s. (The Federal Trade Commission later issued a cease-and-desist order accusing the company of making misleading or false claims, based in part on a study he coauthored.)
Though Dr. Seeram had not previously researched maple, he told The Examination he was intrigued because he had recently moved to the Northeast, where it is an important agricultural product. Over the next couple of years, Dr. Seeram announced he had discovered dozens of polyphenols in maple syrup, including one his team named Quebecol.
Based on his lab tests of concentrated compounds, he began suggesting that maple syrup had wide-ranging applications for human health.
“Maple syrup is becoming a champion food,” he said in a 2011 press release. “Several of these compounds possess antioxidant and anti-inflammatory properties, which have been shown to fight cancer, diabetes and bacterial illnesses.”
But experts say the low levels of these compounds in syrup are unlikely to improve health. Dr. Seeram acknowledged in interviews that a person would have to consume gallons of maple syrup to get the nutritional equivalent of the extracts. He noted, as he often has, that he isn’t encouraging anyone to consume more sugar, merely to choose maple syrup over alternatives.
The U.S. Department of Agriculture, another important benefactor, awarded more than $2.6 million for Dr. Seeram’s work. This included nearly $500,000 in 2017 to study whether maple syrup extract could improve the health of obese mice. Their health did not improve, and in some cases worsened, according to study findings cited by a government website and a student dissertation. The results weren’t published in an academic journal. Dr. Seeram, who in recent weeks stopped responding to queries from The Examination and The Times, didn’t answer questions about this study.
In 2018, the U.S.D.A. awarded $500,000 to a group led by Dr. Seeram for a promotional campaign that would showcase maple research on a University of Rhode Island website. Dr. Seeram’s grant application said he would be responsible for translating the science into “lay-friendly terminology.”
The website, overseen by his team, called maple syrup “immensely healthy for you.” And though it carried disclaimers that more research was needed, it made misleading statements connecting studies of reduced-sugar maple extract to the consumption of maple syrup, such as: “Did you ever think that you could fight high blood sugar with some things as sugary and delicious as maple syrup?”
It also said the Quebecol compound could become a “potential cancer prevention drug,” noting that it looked “remarkably similar” to the breast cancer drug Tamoxifen — a comparison Dr. Seeram has also made in presentations.
In interviews, three cancer researchers called this comparison misleading. Geoffrey Greene of the University of Chicago said it was like expecting the brother of a concert violinist to also be a concert violinist because they looked similar.
When asked why he has used his research to promote maple products, Dr. Seeram said he was simply fulfilling the terms of the government grant. A U.S.D.A. spokeswoman said the University of Rhode Island was responsible for the website’s claims.
The university wouldn’t comment on the research. After inquiries from reporters, the website was taken down. The university said this was part of a broader effort to remove dormant pages.
One of Dr. Seeram’s studies involved giving maple syrup extract to genetically modified worms to examine Alzheimer’s-related effects. His team observed that some worms fared better, but on average they were worse off. Nevertheless, the top-line summary in Dr. Seeram’s paper, published in 2016 by the journal Neurochemical Research, ignored the negative results and said the syrup extract “showed protective effects” for the worms.
An industry association press release said maple syrup extract had prolonged the worms’ lives — even though on average they died sooner — with a disclaimer that more research was needed. That nuance was lost in headlines in Canada, India, England and the United States proclaiming that maple syrup could protect against Alzheimer’s.
Christopher Link of the University of Colorado Boulder, who pioneered Alzheimer’s research on that kind of worm, criticized the study, citing the lack of basic details like the number of worms tested and whether the experiment had been replicated. Dozens of plant extracts have produced positive results in similar experiments, Dr. Link said, but that doesn’t mean they have real-world applications.
In a statement, Julie Barbeau of the maple association said it adheres to strict ethics rules and has had “no influence whatsoever” on the scores of research projects it has backed.
At least a dozen of Dr. Seeram’s papers that the maple association says it funded didn’t disclose that relationship. Also not disclosed in his papers: his paid consultant role and a Canadian maple extract patent that names him and Ms. Barbeau as co-inventors.
Six publishers of Dr. Seeram’s work said they require authors to declare potential conflicts of interest. Dr. Seeram did not respond to questions about his disclosures.
In public statements, he has acknowledged receiving financial support from the maple association. And in earlier interviews, he said that industry funding is vital, because other research dollars are scarce. He also defended his patents, saying, “The driver here is not for me to get rich.” The maple association said it was protecting its intellectual property.
Last year, the association hailed a new study, which it funded, as the “first human clinical trial” of maple syrup.
Participants replaced a small amount of sugar in their diet with maple syrup — for instance, to sweeten coffee. The scientists told Newsweek that the results, published in The Journal of Nutrition, showed that maple syrup improved measures of blood sugar, blood pressure and fat, and might help lower the risk of diabetes and cardiovascular disease.
Dr. Seeram, who was not an author of the study, said the results validated his work.
But three independent experts who reviewed the research said the conclusions were overstated — emphasizing a few positive results among dozens of measures — and the study appeared to show no meaningful difference between maple syrup and refined sugar.
“They took it too far,” said Kimber Stanhope, a nutritional biologist at the University of California, Davis.
The lead researcher, André Marette of Laval University, said that while the differences between maple syrup and refined sugar were “modest,” they were meaningful. Through a public relations firm hired by the industry association, he said, “We were careful to state that the clinical relevance of the work will need to be further substantiated.”
In the meantime, the findings have reached the general public. “Sweet!” effused a headline in a women’s magazine last fall. “Maple Syrup in Coffee Could Help You Lose Weight.”
Mago Torres contributed reporting.
Science
Contributor: With high deductibles, even the insured are functionally uninsured
I recently saw a patient complaining of shortness of breath and a persistent cough. Worried he was developing pneumonia, I ordered a chest X-ray — a standard diagnostic tool. He refused. He hadn’t met his $3,000 deductible yet, and so his insurance would have required him to pay much or all of the cost for that scan. He assured me he would call if he got worse.
For him, the X-ray wasn’t a medical necessity, but it would have been a financial shock he couldn’t absorb. He chose to gamble on a cough, and five days later, he lost — ending up in the ICU with bilateral pneumonia. He survived, but the cost of his “savings” was a nearly fatal hospital stay and a bill that will quite likely bankrupt him. He is lucky he won’t be one of the 55,000 Americans to die from pneumonia each year.
As a physician associate in primary care, I serve as a frontline witness to this failure of the American approach to insurance. Medical professionals are taught that the barrier to health is biology: bacteria, viruses, genetics. But increasingly, the barrier is a policy framework that pressures insured Americans to gamble with their lives. High-deductible health plans seem affordable because their monthly premiums are lower than other plans’, but they create perverse incentives by discouraging patients from seeking and accepting diagnostics and treatments — sometimes turning minor, treatable issues into expensive, life-threatening emergencies. My patient’s gamble with his lungs is a microcosm of the much larger gamble we are taking with the American public.
The economic theory underpinning these high deductibles is known as “skin in the game.” The idea is that if patients are responsible for the first few thousand dollars of their care, they will become savvy consumers, shopping around for the best value and driving down healthcare costs.
But this logic collapses in the exam room. Healthcare is not a consumer good like a television or a used car. My patient was not in a position to “shop around” for a cheaper X-ray, nor was he qualified to determine if his cough was benign or deadly. The “skin in the game” theory assumes a level of medical literacy and market transparency that simply doesn’t exist in a moment of crisis. You can compare the specs of two SUVs; you cannot “shop around” for a life-saving diagnostic while gasping for air.
A 2025 poll from the Kaiser Family Foundation points to this reality, finding that up to 38% of insured American adults say they skipped or postponed necessary healthcare or medications in the past 12 months because of cost. In the same poll, 42% of those who skipped care admitted their health problem worsened as a result.
This self-inflicted public health crisis is set to deteriorate further. The Congressional Budget Office estimates roughly 15 million people will lose health coverage and become uninsured by 2034 because of Medicaid and Affordable Care Act marketplace cuts. That is without mentioning the millions more who will see their monthly premiums more than double if premium tax credits are allowed to expire. If that happens, not only will millions become uninsured but also millions more will downgrade to “bronze” plans with huge deductibles just to keep their premiums affordable. We are about to flood the system with “insured but functionally uninsured” patients.
I see the human cost of this “functional uninsurance” every week. These are patients who technically have coverage but are terrified to use it because their deductibles are so large they may exceed the individuals’ available cash or credit — or even their net worth. This creates a dangerous paradox: Americans are paying hundreds of dollars a month for a card in their wallet they cannot afford to use. They skip the annual physical, ignore the suspicious mole and ration their insulin — all while technically insured. By the time they arrive at my clinic, their disease has often progressed to a catastrophic event, from what could have been a cheap fix.
Federal spending on healthcare should not be considered charity; it is an investment in our collective future. We cannot expect our children to reach their full potential or our workforce to remain productive if basic healthcare needs are treated as a luxury. Inaction by Congress and the current administration to solve this crisis is legislative malpractice.
In medicine, we are trained to treat the underlying disease, not just the symptoms. The skipped visits and ignored prescriptions are merely symptoms; the disease is a policy framework that views healthcare as a commodity rather than a fundamental necessity. If we allow these cuts to proceed, we are ensuring that the American workforce becomes sicker, our hospitals more overwhelmed and our economy less resilient. We are walking willingly into a public health crisis that is entirely preventable.
Joseph Pollino is a primary care physician associate in Nevada.
Insights
L.A. Times Insights delivers AI-generated analysis on Voices content to offer all points of view. Insights does not appear on any news articles.
Viewpoint
Perspectives
The following AI-generated content is powered by Perplexity. The Los Angeles Times editorial staff does not create or edit the content.
Ideas expressed in the piece
-
High-deductible health plans create a barrier to necessary medical care, with patients avoiding diagnostics and treatments due to out-of-pocket cost concerns[1]. Research shows that 38% of insured American adults skipped or postponed necessary healthcare or medications in the past 12 months because of cost, with 42% reporting their health worsened as a result[1].
-
The economic theory of “skin in the game”—which assumes patients will shop around for better healthcare values if they have financial responsibility—fails in medical practice because patients lack the medical literacy to make informed decisions in moments of crisis and cannot realistically compare pricing for emergency or diagnostic services[1].
-
Rising deductibles are pushing enrollees toward bronze plans with deductibles averaging $7,476 in 2026, up from the average silver plan deductible of $5,304[1][4]. In California’s Covered California program, bronze plan enrollment has surged to more than one-third of new enrollees in 2026, compared to typically one in five[1].
-
Expiring federal premium tax credits will more than double out-of-pocket premiums for ACA marketplace enrollees in 2026, creating an expected 75% increase in average out-of-pocket premium payments[5]. This will force millions to either drop coverage or downgrade to bronze plans with massive deductibles, creating a population of “insured but functionally uninsured” people[1].
-
High-deductible plans pose particular dangers for patients with chronic conditions, with studies showing adults with diabetes involuntarily switched to high-deductible plans face 11% higher risk of hospitalization for heart attacks, 15% higher risk for strokes, and more than double the likelihood of blindness or end-stage kidney disease[4].
Different views on the topic
-
Expanding access to health savings accounts paired with bronze and catastrophic plans offers tax advantages that allow higher-income individuals to set aside tax-deductible contributions for qualified medical expenses, potentially offsetting higher out-of-pocket costs through strategic planning[3].
-
Employers and insurers emphasize that offering multiple plan options with varying deductibles and premiums enables employees to select plans matching their individual needs and healthcare usage patterns, allowing those who rarely use healthcare to save money through lower premiums[2]. Large employers increasingly offer three or more medical plan choices, with the expectation that employees choosing the right plan can unlock savings[2].
-
The expansion of catastrophic plans with streamlined enrollment processes and automatic display on HealthCare.gov is intended to make affordable coverage more accessible for certain income groups, particularly those above 400% of federal poverty level who lose subsidies[3].
-
Rising healthcare costs, including specialty drugs and new high-cost cell and gene therapies, are significant drivers requiring premium increases regardless of plan design[5]. Some insurers are managing affordability by discontinuing costly coverage—such as GLP-1 weight-loss medications—to reduce premium rate increases for broader plan members[5].
Science
Trump administration slashes number of diseases U.S. children will be regularly vaccinated against
The U.S. Department of Health and Human Services announced sweeping changes to the pediatric vaccine schedule on Monday, sharply cutting the number of diseases U.S. children will be regularly immunized against.
Under the new guidelines, the U.S. still recommends that all children be vaccinated against measles, mumps, rubella, polio, pertussis, tetanus, diphtheria, Haemophilus influenzae type B (Hib), pneumococcal disease, human papillomavirus (HPV) and varicella, better known as chickenpox.
Vaccines for all other diseases will now fall into one of two categories: recommended only for specific high-risk groups, or available through “shared clinical decision-making” — the administration’s preferred term for “optional.”
These include immunizations for hepatitis A and B, rotavirus, respiratory syncytial virus (RSV), bacterial meningitis, influenza and COVID-19. All these shots were previously recommended for all children.
Insurance companies will still be required to fully cover all childhood vaccines on the CDC schedule, including those now designated as optional, according to the Department of Health and Human Services.
Health Secretary Robert F. Kennedy Jr., a longtime vaccine critic, said in a statement that the new schedule “protects children, respects families, and rebuilds trust in public health.”
But pediatricians and public health officials widely condemned the shift, saying that it would lead to more uncertainty for patients and a resurgence of diseases that had been under control.
“The decision to weaken the childhood immunization schedule is misguided and dangerous,” said Dr. René Bravo, a pediatrician and president of the California Medical Assn. “Today’s decision undermines decades of evidence-based public health policy and sends a deeply confusing message to families at a time when vaccine confidence is already under strain.”
The American Academy of Pediatrics condemned the changes as “dangerous and unnecessary,” and said that it will continue to publish its own schedule of recommended immunizations. In September, California, Oregon, Washington and Hawaii announced that those four states would follow an independent immunization schedule based on recommendations from the AAP and other medical groups.
The federal changes have been anticipated since December, when President Trump signed a presidential memorandum directing the health department to update the pediatric vaccine schedule “to align with such scientific evidence and best practices from peer, developed countries.”
The new U.S. vaccination guidelines are much closer to those of Denmark, which routinely vaccinates its children against only 10 diseases.
As doctors and public health experts have pointed out, Denmark also has a robust system of government-funded universal healthcare, a smaller and more homogenous population, and a different disease burden.
“The vaccines that are recommended in any particular country reflect the diseases that are prevalent in that country,” said Dr. Kelly Gebo, dean of the Milken Institute School of Public Health at George Washington University. “Just because one country has a vaccine schedule that is perfectly reasonable for that country, it may not be at all reasonable” elsewhere.
Almost every pregnant woman in Denmark is screened for hepatitis B, for example. In the U.S., less than 85% of pregnant women are screened for the disease.
Instead, the U.S. has relied on universal vaccination to protect children whose mothers don’t receive adequate care during pregnancy. Hepatitis B has been nearly eliminated in the U.S. since the vaccine was introduced in 1991. Last month, a panel of Kennedy appointees voted to drop the CDC’s decades-old recommendation that all newborns be vaccinated against the disease at birth.
“Viruses and bacteria that were under control are being set free on our most vulnerable,” said Dr. James Alwine, a virologist and member of the nonprofit advocacy group Defend Public Health. “It may take one or two years for the tragic consequences to become clear, but this is like asking farmers in North Dakota to grow pineapples. It won’t work and can’t end well.”
Science
For Oprah Winfrey, a croissant is now just a croissant — not a struggle
Yes, Oprah Winfrey has discussed her weight loss and weight gain and weight in general before — many, many times before. The difference this time around, she says, is how little food noise there is in her daily life, and how little shame. It’s so quiet, in fact, that she can eat a whole croissant and simply acknowledge she had breakfast.
“Food noise,” for those who don’t experience it, is a virtually nonstop mental conversation about food that, according to Tufts Medicine, rarely shuts up and instead drives a person “to eat when they’re not hungry, obsess over meals and feel shame or guilt about their eating habits.”
“This type of obsessive food-related thinking can override hunger cues and lead to patterns of overeating, undereating or emotional eating — especially for people who are overweight,” Tufts said.
Winfrey told People in an exclusive interview published Tuesday that in the past she would have been thinking, “‘How many calories in that croissant? How long is it going to take me to work it off? If I have the croissant, I won’t be able to have dinner.’ I’d still be thinking about that damn croissant!”
What has changed is her acceptance 2½ years ago that she has a disease, obesity, and that this time around there was something not called “willpower” to help her manage it.
The talk show host has been using Mounjaro, one of the GLP-1 drugs, since 2023. The weight-loss version of Mounjaro is Zepbound, like Wegovy is the weight-loss version of Ozempic. Trulicity and Victroza are also GLP-1s, and a pill version of Wegovy was just approved by the FDA.
When she started using the injectable, Winfrey told People she welcomed the arrival of a tool to help her get away from the yo-yo path she’d been on for decades. After understanding the science behind it, she said, she was “absolutely done with the shaming from other people and particularly myself” after so many years of weathering public criticism about her weight.
“I have been blamed and shamed,” she said elsewhere in that 2023 interview, “and I blamed and shamed myself.”
Now, on the eve of 2026, Winfrey says her mental shift is complete. “I came to understand that overeating doesn’t cause obesity. Obesity causes overeating,” she told the outlet. “And that’s the most mind-blowing, freeing thing I’ve experienced as an adult.”
She isn’t even sharing her current weight with the public.
Winfrey did take a break from the medication early in 2024, she said, and started to regain weight despite continuing to work out and eat healthy foods. So for Winfrey the obesity prescription will be renewed for a lifetime. C’est la vie seems to be her attitude.
“I’m not constantly punishing myself,” she said. “I hardly recognize the woman I’ve become. But she’s a happy woman.”
Winfrey has to take a carefully managed magnesium supplement and make sure she drinks enough water, she said. The shots are done weekly, except when she feels like she can go 10 or 12 days. But packing clothes for the Australian leg of her “Enough” book tour was an off-the-rack delight, not a trip down a shame spiral. She’s even totally into regular exercise.
Plus along with the “quiet strength” she has found in the absence of food noise, Winfrey has experienced another cool side effect: She pretty much couldn’t care less about drinking alcohol.
“I was a big fan of tequila. I literally had 17 shots one night,” she told People. “I haven’t had a drink in years. The fact that I no longer even have a desire for it is pretty amazing.”
So back to that croissant. How did she feel after she scarfed it down?
“I felt nothing,” she said. “The only thing I thought was, ‘I need to clean up these crumbs.’”
-
World1 week agoHamas builds new terror regime in Gaza, recruiting teens amid problematic election
-
News1 week agoFor those who help the poor, 2025 goes down as a year of chaos
-
Business1 week agoInstacart ends AI pricing test that charged shoppers different prices for the same items
-
Health1 week agoDid holiday stress wreak havoc on your gut? Doctors say 6 simple tips can help
-
Technology1 week agoChatGPT’s GPT-5.2 is here, and it feels rushed
-
Business1 week agoA tale of two Ralphs — Lauren and the supermarket — shows the reality of a K-shaped economy
-
Science1 week agoWe Asked for Environmental Fixes in Your State. You Sent In Thousands.
-
Politics1 week agoThe biggest losers of 2025: Who fell flat as the year closed